News Summary
NegativeFluor delivered a strong Q2 2026 earnings beat ($0.91 vs $0.71 consensus) with record $6B+ in new awards and backlog expansion to $26.9B, but simultaneously cut full-year adjusted EBITDA guidance to $500-525M due to the $175M Mexican JV divestiture and persistent losses from legacy projects. Stock declined 8.3% post-earnings despite the beat, reflecting investor concern over execution risks in the second half as new project margins compress and the Gordie Howe project continues to hemorrhage cash.
Red flags
- •Full-year EBITDA guidance revised downward despite earnings beat, signaling deteriorating outlook
- •Gordie Howe project recorded additional $44M loss in Q2 alone; segment margin pressure expected H2 2026
- •Legacy loss projects (LAX, I-35 Phase II, Gordie Howe) still require ~$94M+ in additional funding through 2026
- •Analyst sentiment deteriorated heading into earnings; Citigroup cut price target from $61 to $56
- •Peak execution on recent awards delayed to late 2027/early 2028, deferring margin benefit
- •Post-earnings stock volatility and 8.3% sell-off suggest market skeptical of forward guidance despite beat
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 1.9M | +442K | $97M | 0.9% | +31% | Existing |
| Duquesne Family Office | Stanley Druckenmiller | 982K | +982K | $51M | 1.2% | — | NEW |
| Point72 | Steve Cohen | 832K | +832K | $44M | <0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where FLR ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #21 of this fund's book
- 18Bitdeer Technologies Group$65M
- 19Crh Plc$59M
- 20Delta Air Lines Inc$56M
- 21Fluor Corp$51M
- 22D R Horton Inc$49M
- 23Coupang Inc$46M
- 24Advanced Micro Devices Inc$42M
position #35 of this fund's book
- 32NEWAMSTERDAM PHARMA COMPANY$111M
- 33BIO-TECHNE CORP$108M
- 34ROIVANT SCIENCES LTD$100M
- 35FLUOR CORP$97M
- 36VERADERMICS INC$97M
- 37MIRION TECHNOLOGIES INC$94M
- 38VAXCYTE INC$94M
Values are quarter-end position sizes. Shown only for funds where FLR ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Bechelany Pierre Edward | Group President | SELL | 5K | $55.24 | $0.28M | 2026-08-07 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Vanguard Capital Management | SC 13G | 7.9M | 5.5% | 2026-04-29 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.